Suppr超能文献

重构基于拉施模型构建的1型强直性肌营养不良症活动与参与量表。

Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.

作者信息

Hermans Mieke C E, Hoeijmakers Janneke G J, Faber Catharina G, Merkies Ingemar S J

机构信息

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Neurology, Spaarne Hospital, Hoofddorp, The Netherlands.

出版信息

PLoS One. 2015 Oct 20;10(10):e0139944. doi: 10.1371/journal.pone.0139944. eCollection 2015.

Abstract

INTRODUCTION

A previously published Rasch-built activity and participation scale specifically designed for patients with myotonic dystrophy type 1 (DM1) was criticized for having been constructed in a relatively small cohort of patients and containing items too broadly phrased for DM1 patients, thus hampering its clinical use.

METHODS

We report the results of the reconstructed Rasch-built DM1 activity and participation scale for clinical use (DM1-ActivC) through Rasch analyses using an expanded questionnaire containing 146 more simply phrased activity and participation inquiries completed by 340 patients with DM1.

RESULTS

Through stepwise investigation including data quality control, model fit, response category ordering, local dependency and item bias, we succeeded in reconstructing the DM1-ActivC consisting of 25 items that showed good Rasch model fit, including construct convergent validity, items' weights and persons' locations reliability, and unidimensionality.

CONCLUSION

The DM1-ActivC scale has been reconstructed and fulfills all modern clinimetric requirements. Its use is recommended in future longitudinal trials in patients with DM1 to determine its responsiveness.

摘要

引言

先前发表的一个专门为1型强直性肌营养不良症(DM1)患者构建的Rasch活动和参与量表受到批评,原因是该量表是在相对较小的患者队列中构建的,且包含的项目对DM1患者来说表述过于宽泛,从而妨碍了其临床应用。

方法

我们报告了通过Rasch分析重建的用于临床的Rasch构建的DM1活动和参与量表(DM1-ActivC)的结果,使用的是一份扩展问卷,其中包含由340名DM1患者完成的146项表述更简单的活动和参与询问。

结果

通过包括数据质量控制、模型拟合、反应类别排序、局部依赖性和项目偏差在内的逐步调查,我们成功重建了由25个项目组成的DM1-ActivC,该量表显示出良好的Rasch模型拟合,包括结构收敛效度、项目权重和人员位置可靠性以及单维度性。

结论

DM1-ActivC量表已被重建并满足所有现代临床测量学要求。建议在未来针对DM1患者的纵向试验中使用该量表,以确定其反应性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d185/4618741/7f42a9926be6/pone.0139944.g001.jpg

相似文献

1
Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.
PLoS One. 2015 Oct 20;10(10):e0139944. doi: 10.1371/journal.pone.0139944. eCollection 2015.
2
Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ).
Neuromuscul Disord. 2010 May;20(5):310-8. doi: 10.1016/j.nmd.2010.03.010. Epub 2010 Apr 2.
3
Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.
Muscle Nerve. 2013 Jan;47(1):89-95. doi: 10.1002/mus.23478. Epub 2012 Oct 5.
4
Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?
Arch Phys Med Rehabil. 2018 Sep;99(9):1776-1782.e9. doi: 10.1016/j.apmr.2018.02.017. Epub 2018 Apr 3.
5
Improving assessment in small fiber neuropathy.
J Peripher Nerv Syst. 2015 Sep;20(3):333-40. doi: 10.1111/jns.12128.
6
How to capture activities of daily living in myotonic dystrophy type 2?
Neuromuscul Disord. 2020 Oct;30(10):796-806. doi: 10.1016/j.nmd.2020.07.011. Epub 2020 Aug 1.
8
Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.
Muscle Nerve. 2017 Jul;56(1):86-92. doi: 10.1002/mus.25469. Epub 2017 Mar 1.
9
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.
10
Rasch analysis of Dutch-translated version of the Foot Impact Scale for rheumatoid arthritis.
Rheumatology (Oxford). 2011 Jul;50(7):1315-9. doi: 10.1093/rheumatology/ker003. Epub 2011 Feb 23.

引用本文的文献

2
Myotonic dystrophy type 1: A comparison between the adult- and late-onset subtype.
Muscle Nerve. 2023 Feb;67(2):130-137. doi: 10.1002/mus.27766. Epub 2022 Dec 22.
4
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
Front Aging Neurosci. 2021 Nov 15;13:755392. doi: 10.3389/fnagi.2021.755392. eCollection 2021.
5
Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy.
J Neuromuscul Dis. 2021;8(6):1031-1046. doi: 10.3233/JND-210634.
6
Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1.
Front Neurol. 2020 Oct 7;11:624. doi: 10.3389/fneur.2020.00624. eCollection 2020.
7
Change over time in ability to perform activities of daily living in myotonic dystrophy type 1.
J Neurol. 2020 Nov;267(11):3235-3242. doi: 10.1007/s00415-020-09970-6. Epub 2020 Jun 15.
8
Analysis of the functional capacity outcome measures for myotonic dystrophy.
Ann Clin Transl Neurol. 2019 Aug;6(8):1487-1497. doi: 10.1002/acn3.50845. Epub 2019 Jul 22.
9
Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI.
Neurology. 2019 Jun 11;92(24):e2803-e2814. doi: 10.1212/WNL.0000000000007648. Epub 2019 May 22.

本文引用的文献

1
Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness.
Neurology. 2014 Dec 2;83(23):2124-32. doi: 10.1212/WNL.0000000000001044. Epub 2014 Nov 5.
2
Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
Biochim Biophys Acta. 2015 Apr;1852(4):594-606. doi: 10.1016/j.bbadis.2014.05.019. Epub 2014 May 29.
3
Daytime sleepiness and myotonic dystrophy.
Curr Neurol Neurosci Rep. 2013 Apr;13(4):340. doi: 10.1007/s11910-013-0340-9.
4
The Rasch-built Pompe-specific activity (R-PAct) scale.
Neuromuscul Disord. 2013 Mar;23(3):256-64. doi: 10.1016/j.nmd.2012.10.024. Epub 2012 Dec 28.
6
Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.
Muscle Nerve. 2013 Jan;47(1):89-95. doi: 10.1002/mus.23478. Epub 2012 Oct 5.
7
The use of raw scores from ordinal scales: time to end malpractice?
J Rehabil Med. 2012 Feb;44(2):97-8. doi: 10.2340/16501977-0938.
8
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
Neurology. 2011 Jan 25;76(4):337-45. doi: 10.1212/WNL.0b013e318208824b.
9
Perspectives on gene therapy in myotonic dystrophy type 1.
J Neurosci Res. 2011 Mar;89(3):275-85. doi: 10.1002/jnr.22551. Epub 2010 Dec 16.
10
On the theory of scales of measurement.
Science. 1946 Jun 7;103(2684):677-80.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验